A phase II dose-ranging study of mirabegron in patients with overactive bladder

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F13%3AE0103853" target="_blank" >RIV/00843989:_____/13:E0103853 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1007/s00192-013-2042-x" target="_blank" >http://dx.doi.org/10.1007/s00192-013-2042-x</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00192-013-2042-x" target="_blank" >10.1007/s00192-013-2042-x</a>

Result language
angličtina
Original language name
A phase II dose-ranging study of mirabegron in patients with overactive bladder
Original language description
Mirabegron is a potent and selective beta(3)-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder. Patients completed a single-blinded, 2-week placebo run-in period followed by 12 weeks of randomized (n = 928) double-blinded treatment with mirabegron oral controlled absorption system (OCAS) 25, 50, 100, or 200 mg once-daily (QD), placebo or tolterodine extended release (ER) 4 mg QD. The primary endpoint was change from baseline to end-of-treatment in mean number of micturition episodes/24 h. Secondary endpoints included changes in mean volume voided per micturition; mean number of urinary incontinence, urgency urinary incontinence, and urgency episodes/24 h; severity ofurgency; nocturia; and quality of life measures. Safety parameters included vital signs, adverse events, laboratory tests, electrocardiogram measurements and post-void residual volume. Mirabegron 25, 50, 100, and 200 mg resulted in dose-
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FP - Other medical fields
OECD FORD branch
—

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)